Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Nscale, a cloud computing rival of CoreWeave and Nebius, has filed for an IPO. Nscale stock will trade on the NYSE. The post Nscale, Rival Of CoreWeave And Nebius, Files For IPO appeared first on Investor’s Business Daily.
The Anthropic IPO will be delayed until November, the WSJ reported. OpenAI forecast massive negative cash flow, the FT reported. The post Anthropic Reportedly Delays IPO; OpenAI Expects Massive Cash Burn appeared first on Investor’s Business Daily.
The Philadelphia semiconductor index, known as SOX, rose for a fourth consecutive day on Friday, with a new batch of chip stocks leading the charge. The post Chip Stocks Hit Ceiling Amid Sector Rebound. Macom Is A Standout. appeared first…
Netflix stock tanked on Friday after a Wall Street analyst downgraded the streaming video giant to the equivalent of a sell rating. The post Netflix Stock Downgraded To Sell As Viewer Engagement Wanes appeared first on Investor’s Business Daily.
Long before Pope Leo voiced concerns about AI, tech leaders actually warned about ‘AI extinction risks.’ What’s at stake now that fears are spreading. The post When OpenAI, Anthropic CEOs Warned Of ‘AI Extinction Risk’ appeared first on Investor’s Business…
Apple began selling its latest premium smartphones Friday and analysts are cautiously optimistic about its prospects. The post Apple Stock Near Buy Point As iPhone 18 Pro Goes On Sale appeared first on Investor’s Business Daily.
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The post The Biotech Surged 50% On Positive Data In March. Now, It’s Almost Gone.…
Google stock edged up after the federal judge unsealed a detailed remedies decision in an advertising antitrust case. The post Here’s How Google Advertising Antitrust Ruling Could Play Out appeared first on Investor’s Business Daily.
Ultragenyx Pharmaceuticals won approval for its newest gene therapy on Thursday, helping shares partially reverse a catastrophic dive. The post How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive appeared first on Investor’s Business Daily.
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. The post Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout appeared first on Investor’s Business Daily.
